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The effect of sub-lethal concent-rations of isoniazid, ethambutol, rifampicin and
pyrazinamide on the growth in vitro and the production of both exochelins and
mycobactins by the high virulent and the South Indian low virulent strains of M.
tuberculosis was examined under iron-deficient and iron-rich conditions. There was
a marked decrease in the growth of both strains in the presence of increasing
concentrations of all four drugs, the inhibition being total in the presence of minimal
inhibitory concentrations of the drugs. It was also observed that the growth-
inhibitory effect of all four drugs was slightly reversed in the presence of high
concentration of iron in the medium. A significant increase was observed in the
concentrations of both siderophores in the presence of all four drugs, under both
iron-deficient (or) iron-rich conditions.
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I N T R O D U C T I O N
With the onset of infection and an
elevation in the body temperature, the
host limits the availability of essential
nutrients by a process. called nutri-
tional immunity. Of these nutrients,
iron is recognised to be vital for the
survival and proliferation of micro-or-
ganisms within the host. Mycobacteria
also require iron for their survival
within the host. To meet the demand
for iron, mycobacteria synthesize and
utilize specific high affinity iron-bind-
ing compounds which help them grow
in the iron-restricted conditions of the
host1,2. Two types of iron-binding com-
pounds are produced3 : exochelins, oc-
curs extracellulary to act as scavenger
and mycobactin, occurs on the cell wall
to act as transport and as a store for
iron.
Our present knowledge of several
host-defence mechanisms in tubercu-
losis is incomplete, particularly with
respect to nutritional immunity. Thus
for instance, very little is known
about the iron-sequestration mecha-
nism adopted by mycobacteria dur-
ing infections like tuberculosis.
Among the several mechanisms pro-
posed for the action of anti-tubercu-
losis drugs such as isoniazid and
ethambutol against tubercle bacilli is
the capacity of these drugs to chelate
metal ions essential for the growth of
these micro-organisms4. An investi-
gation was therefore undertaken to
study the effect of sub-lethal levels of
these drugs on the growth in vitro
and the production of both exochelins
and mycobactins by the high virulent
H37RV and the South Indian low
virulent (SILV) strains of M. tuberculosis
under iron-deficient and iron-rich
conditions. A similar investigation
was undertaken with other anti-tu-
berculosis drugs such as rifampicin
and pyrazinamide, which are not
known to have any metal ion binding
properties.
Table 1 Effect of sub-lethal concentrations of anti-tuberculosis drugs on the mean
cell dry-weight (of 4 estimates) by the virulent (H37Rv) and the South Indian low
virulent (SILV) strains of M. tuberculosis under iron-deficient (0.02 µg/ml) and iron-
rich (4.0 µg/ml) conditions.
Drug Drug
concentra-
Mean cell dry-weight (g/100 ml) standard deviation
tions
according to stain and iron concentration (µg/ml)
in the
medium H37Rv
SILV
(µg/ml) 0.02 4 . 0 0.02 4.0
Isoniazid 0 0.109 ± 0.01 1.077 ± 0.01 0.087 ± 0.01 0.910 ± 0.02
0.0125 0.046 ± 0.01 0.314 ± 0.01 0.045 ± 0.01 0.205 ± 0.01
0.0250 0.012 ± 0.01 0 .07  ±  0 .01 0.011 ± 0.01 0.057 ± 0.01
0.0500 NG NG NG NG
Ethambutol 0 0.109 ± 0.010 1.077 ± 0.097 0.087 ± 0.007 0.910 ± 0.016
0.5 0.069 ± 0.003 0.397 ± 0.020 0.060 ± 0.002 0.258 ± 0.037
1.0 0.017 ± 0.002 0.093 ± 0.008 0.019 ± 0.001 0.087 ± 0.009
 2.0 NG NG    NG   NG
Rifampicin 0 0.125 ± 0.017 1.074 ± 0.055 0.089 ± 0.003 0.897 ± 0.017
0.0125 0.040 ± 0.002 0.283 ± 0.007 0.043 ± 0.004 0.308 ± 0.011
0.0250 0.013 ± 0.001 0.086 ± 0.003 0.018 ± 0.001 0.073 ± 0.004
0.0500 NG NG NG NG
Pyrazinamide 0 0.125 ± 0.017 1.074 ± 0.055 0.089 ± 0.003 0.897 ± 0.017
2.5 0.070 ± 0.001 0.309 ± 0.007 0.073 ± 0.004 0.315 ± 0.005
5.0 0.017 ± 0.002 0.088 ± 0.005 0.020 ± 0.001 0.088 ± 0.005
10.0 NG NG NG NG
NG= no growth
MATERIAL & METHODS
Organisms and growth in vitro:
The drug-susceptible, high virulent
H37Rv and the South Indian low viru-
lent (SILV) strains of M. tuberculosis
were inoculated into a synthetic
medium (pH 6.8) which was pre-
pared in iron-free glassware. The
minimal inhibitory concentrations of
liquid medium were 0.05 µg/ml for
isoniazid and rifampicin, 2.0 µg/ml
for ethambutol and 10.0 µg/ml for
pyrazinamide. The concentrations of
the drugs employed in the present
experiment were 0, 0.0125, 0.025 and
0.05 µg/ml fir usibuazid (Bayer
Leverkusen, Germany) and rifampicin
(Polfa Tarchomin, Poland), 0, 0.5, 1.0
and 2.0 µg/ml for ethambutol (Sigma,
USA) and 0, 2.5, 5.0 and 10.0 µg/ml
for pyrazinamide (Merck Sharp &
Dohme Ltd, UK). The concentration
of  i ron employed (Fe + + )  in  the
medium were 0.02 and 4.0 µg/ml.
Incubation was at 37°C for 35 days
without shaking.
Determination of cell dry-weight:
Cell dry-weights were determined
using preweighed filters with drying
to constant weight at 100°C.
Extraction and estimation of
exochelins and mycobactins:
Exochelins were converted to their
ferri-complexes and extracted into
chloroform from cell-free culture fil-
trates6. Mycobactins were isolated by
ethanol extraction of freshly har-
vested, moist mycobacterial cells7.
Both the siderophores were estimated
gravimetrically.
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The experiment was set up in
quadriplicate and the estimations
were statistically analysed employing
students t-test (Paired and unpaired).
OBSERVATIONS
There was a significant decrease in
the growth of both H37Rv and SILV
with increasing concentrations of
isoniazid in the medium (P <0.001)
upto the minimal inhibitory concen-
tration of the drug under both iron-
deficient and iron-rich conditions
(Table 1). There was no growth when
isoniazid 0.05 µg/ml (MIC) was added.
to the medium under both iron-defi-
cient and iron-rich conditions. How-
ever, the growth under iron-rich con-
ditions was substantially higher
(p< 0.001) than under iron-deficient
conditions both in the presence and
in the absence of isoniazid in the
medium. The growth of SILV under
iron-deficient (or) iron-rich condi-
tions was significantly lower than
that of H37Rv (P<0.01) in the presence
and in the absence of isoniazid in the
medium.
There was a significant increase in
the release of exochelins of both H37
Rv and SILV with increasing concen-
trations of isoniazid in the medium
(P<0.001) upto the minimal inhibitory
concentration of the drug under both
iron-deficient and iron-rich condi-
t ions  (Table  2 ) .  The  re lease  of
exochelins of H37Rv was significantly
higher (P<0.01) than that of SILV
under both iron-deficient and iron-
Table 2 Effect of sub-lethal concentrations of anti-tuberculosis drugs on the mean
Exochelin concentrations (of 4 estimates) by the virulent (H37Rv) and the South Indian
low virulent (SILV) strains of M.tuberculosis under iron-deficient (0.02 µg/ml) and
Iron-rich (4.0 µg/ml) conditions.
Drug
Isoniazid
Ethambutol
Rifampicin
Drug
concentra-
tions
in the
medium
(µg/ml)
0.0125
0.0250
0.0500
0
0.5
1.0
2.0
0
0.0125
0.0250
0.0500
0
2.5
5.0
10.0
Pyrazinamide 
NE=No Exochelin
Mean cell dry-weight (g/100 ml) *standard deviation
according to stain and iron concentration (µg/ml)
H37
0.02
34.4 ± 03.2
53.3 ± 08.0
85.2 ± 14.1
NE
34.4 ± 03.2
58.5 ± 02.2
74.7 ± 21.4
NE
35.2 ± 2.2
49.5 ± 2.6
80.6 ± 8.4
NE
35.2 ± 2.2
46.7 ± 6.5
59.3 ± 6.4
NE
Rv
4.0
09.5 ± 0.1
19.1 ± 0.6
26.1 ± 2.4
NE
09.5 ± 0.1
16.5 ± 0.7
21.7 ± 1.9
NE
09.8 ± 0.2
17.7 ± 0.4
23.4 ± 0.7
NE
09.8 ± 0.2
14.5 ± 1.6
22.8 ± 1.3
NE
SILV       
0.02
31.5 ± 4.4
38.6 ± 11.3
90.1 ± 11.8
NE
31.5 ± 4.1
38.5 ± 6.7
52.7 ± 2.3
NE
30.9 ± 4.9
46.6 ± 4.3
55.0 ± 3.7
NE
30.9 ± 4.9
41.0 ± 2.3
51.4 ± 3.4
NE
4.0
08.1 ± 0.5
13.4 ± 2.0
17.7 ± 2.2
NE
08.1 ± 0.5
13.7 ± 1.5
23.2 ± 2.6
NE
08.1 ± 0.5
13.0 ± 0.5
27.4 ± 1.5
NE
08.1 ± 0.5
12.8 ± 0.2
22.8 ± 1.3
N E           
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Table 3 Effect of sub-lethal concentrations of anti-tuberculosis drugs on the mean
mycobactin concentrations (of 4 estimates) by the virulent (H37Rv) and the South Indian
low virulent (SILV) strains of M.tuberculosis under iron-deficient (0.02 µg/ml) and
iron-rich (4.0 µg/ml) conditions.
Drug Drug
concentra-
Mean cell dry-weight (g/100 ml) ±standard deviation.
tions according to stain and iron concentration (µg/ml)
in the
medium H37Rv SILV
(µg/ml) 0.02 4.0        0.02 4.0
Isoniazid 0 82.6 ± 02.3 22.6 ± 0.5 54.7 ± 03.1 20.1 ± 1.1
0.125 108.9 ± 06.9 36.1 ± 0.9 66.3 ± 03.0 30.5 ± 1.2
0.0250 145.5 ± 36.5 42.3 ± 4.0 90.1 ± 11.8 59.0 ± 3.8
0.0500 NM NM NM NM
Ethambutol 0 082.6 ± 02.3 22.6 ± 0.5 054.7 ± 3.1 20.1 ± 1.1
0.5 120.4 ±  03.7 30.4 ± 1.0 067.l ± 1.9 30.2 ± 1.4
1.0 136.3 ± 19.6 40.4 ± 3.5 105.5 ± 4.5 40 . l  ± 3.5
2.0 NM NM NM NM     
Rifampicin 0 083.4 ± 02.2 22.9 ± 0.7 053.6 ± 4.4 21.4 ± 0.7
0.0125 104.8 ± 08.3 35.4 ± 0.8 069.8 ± 6.5 27.7 ± 2.8
0.0250 161.3 ± 16.8 42.7 ± 4.7 110.0 ± 7.3 45.0 ± 4.9
0.0500 NM NM NM NM
Pyrazinamide 0 084.8 ± 02.2 22.8 ± 0.7 052.4 ± 4.4 I 21.4 ± 0.7
2.5 103.4 ± 05.7 27.5 ± 1.3 061.3 ± 4.9 27.8 ± 1.2
5.0 118.7 ± 12.8 34.2 ± 2.0 102.9 ± 6.8 42.6 ± 3.8
10.0 NM NM NM NM
NM=No Mycobactin
rich conditions in the presence and in
the absence of isoniazid.
The production of mycobactins of
both H37Rv and SILV also signifi-
cantly increased with increasing con-
centrations of isoniszid in the me-
dium (p<0.001) upto the MIC of the
drug under. both iron-deficient and
iron-rich conditions (Table 3). The
production of mycobactins of H37Rv
was significantly higher (p< 0.001)
than that of SILV under both iron-
deficient and iron-rich conditions in
the presence and in the absence of
isoniazid. The production of both
exochelins and mycobactins was sub-
stantially less under iron-rich condi-
tions than under iron-deficient condi-
tions (p<0.001) in the presence and in
the absence of isoniazid. The effect of
rifampicin, ethambutol and
pyrazinamide on the growth (Table 1)
of H37Rv and SILV and the production
of e x o c h e l i n s  ( T a b l e  2 )  a n d
mycobactins (Table 3) was similar to
that of isoniazid.
DISCUSSION
Among the several mechanisms
proposed for the action of some anti-
tuberculosis drugs such as isoniazid,
ethambutol, p-aminosalicylic acid,
streptomycin and cycloserine is their
capacity to withhold metal ions re-
quired for the growth of tubercle
bacilli by chelation4. There is no 
evidence to suggest that other anti-
tuberculosis drugs such as rifampicin,
ethionamide (or) kanamycin have the
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capacity to hold metal ions. Salicy-
lates and dihydroxy benzoic acids
have been recognized as siderophores
in several bacterial and fungal spe-
cies such as M. smegmatis, Aerobacter
aerogenes, E. coli and certain species
of Salmonella8,9. Rat ledge and
coworker have worked out in detail
the a c t i o n  o f PAS against
M. smegmatis and M. bovis BCG with
respect to acquisition or iron by these
strains10,11. Under conditions of iron
deficiency (0.1 µg/ml), PAS was
shown to strongly inhibit the forma-
tion of mycobactin. Further, uptake
of iron was also inhibited and a
decline was observed in the activity
of several iron-containing enzymes.
Brown & Ratledge11 have suggested
that PAS might be exerting its pri-
mary inhibitory effect by blocking
the transfer of iron from mycobactin
to an intra-cellular acceptor.
Findings presented in this report
show that there is marked decrease in
the growth of both the H37Rv and the
SILV stains in the presence of increas-
ing. concentrations of isoniazid and
ethambutol, the inhibition being total
in the presence of the respective
minimal inhibitory concentrations of
the two drugs. It was also observed
that the growth inhibitory effect was
slightly reversed in the presence of a
high concentration of iron in the
medium. Further, an appreciable
increase was observed in the produc-
tion o f  b o t h  e x o c h e l i n s  a n d
mycobactins, both under iron-defi-
cient and iron-sufficient conditons.
These findings therefore, suggest a
role for these two drugs in the with-
holding of iron from the bacteria.
Surprisingly, however, a very similar
pattern of findings, including a rever-
sal of the growth-inhibitory effect in
the presence of excess iron and an
appreciable increase in the produc-
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tion of both siderophores, was ob-
served with rifampicin and
pyrazinamide, drugs which are no:
known to have any capacity for hold-
ing metal  ion . These findings,
therefores, suggest that the iron-with-
holding effect of isoniazid and
ethambutol is non-specific. The in-
crease in the production of both
sidephores might also be a non
specific reaction of the bacilli in an
attempt to survive under conditions
inimical to growth.
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